US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

25.43 +0.08 (+0.32%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes
Via ACCESSWIRE
News headline image
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2023
Via ACCESSWIRE
News headline image
Amphastar Pharma: Q1 Earnings Insights ↗
 
Via Benzinga
News headline image
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals to Present at the Wells Fargo Healthcare Conference
Via ACCESSWIRE
News headline image
Eli Lilly (LLY) Stock Up Almost 50% Year to Date: Here's Why ↗
Eli Lilly and Company (LLY​​​​​​​) boasts a solid portfolio of core drugs in diabetes, autoimmune diseases and cancer. 
Via Talk Markets
News headline image
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2023
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals Completes Acquisition of BAQSIMI from Lilly
Via ACCESSWIRE
News headline image
Earnings Outlook For Amphastar Pharma ↗
 
Via Benzinga
News headline image
Lilly to Divest BAQSIMI to Amphastar
Via ACCESSWIRE
News headline image
Promising Small Biotech Amphastar Sees Actionable Pullback
Small-cap Amphastar Pharmaceuticals is pulling back from recent highs in an orderly fashion, potentially offering a new entry point after beating Q1 views. 
Via MarketBeat
News headline image
Abcam Stock Earns Relative Strength Rating Upgrade ↗
A Relative Strength Rating upgrade for Abcam ADR shows improving technical performance. 
Via Investor's Business Daily
Amphastar Pharmaceuticals Inc. (NASDAQ: AMPH) Records 52-Week High Tuesday Morning
Via Investor Brand Network
News headline image
FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90 ↗
On Tuesday, FibroGen stock saw a positive improvement to its Relative Strength Rating, rising to 94 from 90 a day earlier. 
Via Investor's Business Daily
News headline image
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
Via ACCESSWIRE
News headline image
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023
Via ACCESSWIRE
News headline image
Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating ↗
On Wednesday, Inhibrx stock now clears that desired 80-plus Relative Strength threshold, with a jump from 80 to 86 Wednesday. 
Via Investor's Business Daily
News headline image
Eli Lilly Divests Low Blood Sugar Drug Baqsimi To Amphastar For $500M Cash ↗
 
Via Benzinga
News headline image
Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023
Via ACCESSWIRE
News headline image
Genmab Stock Hits 80-Plus Relative Strength Rating Benchmark ↗
On Monday, Genmab stock saw its Relative Strength (RS) Rating jump into the 80-plus percentile, rising to 84, up from 80 the day before. 
Via Investor's Business Daily
News headline image
Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
News headline image
Emergent BioSolutions Soars: Analyst Upgrades Stock With Near 100% Upside After FDA's Positive Move ↗
 
Via Benzinga
News headline image
BioMarin Pharmaceutical Stock Shows Rising Relative Strength ↗
BioMarin Pharmaceutical stock had its Relative Strength Rating upgraded to 77 on Thursday, up from 70 a day earlier. 
Via Investor's Business Daily
News headline image
Alkermes Stock Sees Rising Relative Strength Rating ↗
The Relative Strength (RS) Rating for Alkermes stock climbed into a new percentile Tuesday, as it got a lift from 69 to 77. 
Via Investor's Business Daily
News headline image
Exelixis Stock Shows Rising Relative Price Performance; Still Shy Of Key Benchmark ↗
In a welcome move, Exelixis stock saw its Relative Strength Rating improve to 73 on Monday, up from 69 a day earlier. 
Via Investor's Business Daily
News headline image
BioMarin Pharmaceutical Stock Sees IBD RS Rating Improve To 74 ↗
A Relative Strength Rating upgrade for BioMarin Pharmaceutical shows improving technical performance. Will it continue? 
Via Investor's Business Daily
News headline image
Exelixis Stock Generating Improved Relative Strength Rating ↗
Exelixis stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 69 to 76. 
Via Investor's Business Daily
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >